Physician profile
Sarah E Mann
NPI 1437161643
$1,401.08
in general payments reported to CMS, 2019-2025
16 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.41 · 2023: $432 · 2024: $483 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $480.00 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $258.33 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.11 | 2023-2025 | |
| Exact Sciences Corporation | $78.32 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $70.99 | 2023-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $53.62 | 2024-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.29 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $41.70 | 2025 | |
| Sumitomo Pharma America, INC. | $41.60 | 2024-2025 | Gemtesa |
| Amgen INC. | $33.40 | 2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $31.68 | 2023-2024 | Shingrix, Arexvy |
| Pfizer INC. | $29.20 | 2025 | |
| Abbott Laboratories | $23.95 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $17.28 | 2023 | Breztri |
| Dynavax Technologies Corporation | $15.20 | 2023 | Heplisav-B |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.